FDA CRL Delays ViiV’s Long-Acting Cabotegravir Regimen
Manufacturing Questions Triggered FDA Complete Response Letter
ViiV Healthcare will not be able to launch its cabotegravir and rilpivirine long-acting HIV treatment in January after receiving an FDA Complete Response Letter.
You may also be interested in...
ViiV unblinded the Phase III study on positive data, and it plans to pursue approval in H1 2021.
The sponsors of 11 new treatments should learn this week whether the European Medicines Agency will recommend EU marketing approval for their products.
New oncology and immunology products are moving rapidly through GSK’s refocused research pipeline, including new agents for multiple myeloma, endometrial and head and neck cancer, adding to efforts against COVID-19, respiratory syncytial virus infection and HIV/AIDS.